Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark C Genovese

Showing results (81-90 of 164) with videos related to

Pageof 17
Sort By:
The Journal of Rheumatology|April 17, 2012
Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD studyMark C Genovese, Chenglong Han, Edward C Keystone, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 25, 2017
Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid ArthritisMark C Genovese, Maria Greenwald, Christine Codding, et al.
Rheumatology (Oxford, England)|December 26, 2016
Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trialsRobert J Moots, Anthony Sebba, William Rigby, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 14, 2014
A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitorsMark C Genovese, Maria Greenwald, Chul-Soo Cho, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 17, 2014
Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyMichael E Weinblatt, Mark C Genovese, Meilien Ho, et al.
The Journal of Rheumatology|December 17, 2015
Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD TrialEdward C Keystone, Mark C Genovese, Stephen Hall, et al.
Arthritis Research & Therapy|August 16, 2020
Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritisJosef S Smolen, Young Mo Kang, Wan-Hee Yoo, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|December 21, 2013
Effect of golimumab on carotid atherosclerotic disease measures and cardiovascular events in inflammatory arthritidesMary Chester Wasko, Elizabeth C Hsia, Bruce Kirkham, et al.
The Journal of Rheumatology|June 2, 2004
The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritisKaren E Hansen, Julie P Hildebrand, Mark C Genovese, et al.
Annals of the Rheumatic Diseases|May 7, 2010
Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD studyEdward Keystone, Mark C Genovese, Lars Klareskog, et al.
Pageof 17

Showing results (81-90 of 164) with videos related to

Sort By:
Pageof 17
The Journal of Rheumatology|April 17, 2012
Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD studyMark C Genovese, Chenglong Han, Edward C Keystone, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 25, 2017
Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid ArthritisMark C Genovese, Maria Greenwald, Christine Codding, et al.
Rheumatology (Oxford, England)|December 26, 2016
Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trialsRobert J Moots, Anthony Sebba, William Rigby, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 14, 2014
A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitorsMark C Genovese, Maria Greenwald, Chul-Soo Cho, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 17, 2014
Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyMichael E Weinblatt, Mark C Genovese, Meilien Ho, et al.
The Journal of Rheumatology|December 17, 2015
Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD TrialEdward C Keystone, Mark C Genovese, Stephen Hall, et al.
Arthritis Research & Therapy|August 16, 2020
Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritisJosef S Smolen, Young Mo Kang, Wan-Hee Yoo, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|December 21, 2013
Effect of golimumab on carotid atherosclerotic disease measures and cardiovascular events in inflammatory arthritidesMary Chester Wasko, Elizabeth C Hsia, Bruce Kirkham, et al.
The Journal of Rheumatology|June 2, 2004
The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritisKaren E Hansen, Julie P Hildebrand, Mark C Genovese, et al.
Annals of the Rheumatic Diseases|May 7, 2010
Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD studyEdward Keystone, Mark C Genovese, Lars Klareskog, et al.
Pageof 17